Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys Biogen (BIIB) Stock
Rep. Gilbert Ray Cisneros Jr. acquired shares of Biogen valued between $1,001 and $15,000.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Biogen Inc. ($BIIB) stock on June 5, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed July 2, 2026.
Since the trade, $BIIB is up 2.4% after 1 week, up 6.7% after 1 month and up 19.1% to date (from the $195.34 close on Jun 5, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Jul 2, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Biogen Inc. ($BIIB) | Buy | Jun 5, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
BIIB
Biogen Inc.
Key Points
- On June 5, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Biogen Inc. (BIIB) valued between $1,001 and $15,000.
- Biogen's stock was trading at $233.54 on the day of the transaction, slightly above its 52-week low of $135.39.
- The company has a market cap of about $32.4 billion and a P/E ratio of 39.0, indicating investor interest.
Get $BIIB trade alerts by text
We text you when insiders, Congress or big funds trade $BIIB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Biogen Inc. (NasdaqGS: BIIB) on June 5, 2026. The transaction was valued between $1,001 and $15,000. The reported date for this transaction was July 2, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
Inside Gilbert Ray Cisneros Jr.'s Trade
Cisneros's recent purchase adds to his investment profile, which includes a previous sale of shares from other companies on the same day. His latest action shows a commitment to Biogen, which operates in the healthcare sector, focusing on drug manufacturing and therapies.
Other Institutional Activity in Biogen
Several institutional investors have also been active with Biogen shares. FMR, LLC raised its holdings by 5,409,844 shares, totaling 18,217,239 shares worth about $4.27 billion. Blackrock Inc. added 11,182 shares, bringing its total to 15,985,736 shares valued at around $3.75 billion. Primecap Management Company increased its stake by 396,980 shares, ending with 15,154,606 shares worth about $3.56 billion. Vanguard Capital Management LLC grew its position by 113,498 shares, totaling 9,651,117 shares valued at approximately $2.26 billion. State Street Corporation also increased its holdings by 176,333 shares, totaling 7,344,327 shares worth about $1.72 billion.
Biogen Inc. Stock Down 0.8%
Biogen's shares were trading at $233.54 on the day of Cisneros's purchase, sitting above its 52-week low of $135.39 and close to its high of $225.80. The stock has shown a stable performance recently, with a P/E ratio of 39.0, suggesting that investors are willing to pay a premium for future growth.
Recent Earnings
Biogen reported revenue of approximately $10.03 billion, with a revenue growth rate of 3.4%. The company had an EPS of $5.62, with a net margin of 8.3%. Its next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
-
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
5 target raises, 1 target cut.
-
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.
Earnings Call Summary
Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.
Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.
Slightly positive report. The quarter was acceptable, but the forward setup is not strong.
Insider Buying and Selling at Biogen Inc.
On August 4, 2026, Director Minor Lloyd B. sold 1,186 shares valued at about $239,750. Officer Nicole Murphy bought 3 shares on February 12, 2026, at an average price of $195.04, totaling $585. On February 9, 2026, Officer Priya Singhal sold 2,660 shares valued at approximately $531,548.
Analysts Set New Price Targets
Analysts have been optimistic about Biogen's future. On October 12, 2026, JP Morgan upgraded the stock to an Overweight rating with a new price target of $300, up from $210. UBS maintained a Buy rating with a target of $270, increasing from $240. RBC Capital also kept an Outperform rating with a target of $256, slightly down from $260.
About Biogen
Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, MA, Biogen has a significant presence in the healthcare industry and is known for its innovative treatments.
Bottom Line
Investors should keep an eye on Biogen's upcoming earnings report on October 28, 2026, as well as any further stock activity from Cisneros. This transaction is part of a broader pattern of recent trades by the congressman, highlighting his investment strategy. Remember, the reported trades reflect positions as of their respective dates and may not represent current holdings.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $BIIB (Jun 5, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts